DALLAS , Sept. 9, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the Retina Society 57 th Annual Scientific Meeting and at Advanced Therapies Europe taking place during the 2 nd week of September in Lisbon, Portugal .
Details for the presentations are as follows: Title: BCVA Analysis of Patients Treated with Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 100-week TOPLINE Results from a Phase 2b /3 Randomized, Sham-Controlled Clinical Trial (RESTORE) Session Title: Genetic Diseases, Dystrophies & Degenerations Session Date: September 11, 2024 Session Time: 4:25 p.m. WEST Location: Pedro Leitao Ballroom, Four Seasons Hotel Ritz, Lisbon Presenter: Anat Loewenstein , MD, MHA, Professor and Director, Division of Ophthalmol.
, Tel Aviv University In her presentation, Dr. Loewenstein will highlight the end-of-study 100 week RESTORE data from mutation-agnostic Multi-Characteristic Opsin (MCO) therapy of severe vision loss due to retinitis pigmentosa. Title: Democratizing Gene Therapy for Neurodegenerative Diseases Session Title: Gene Therapy: Spotlight on Developments and Breakthroughs Session Date: September 11, 2024 Session Time: 4:15 p.
m. WEST Location: Estoril Convention Center, Lisbon Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer During his presentation, Dr. Mohanty will highligh.